aap without one-time effects, sales of the first half of 2009 are
slightly below previous year's
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
aap Implantate AG, a medical technology company listed on the
Frankfurt Stock Exchange in the Prime Standard segment achieved in
the first six months of the financial year 2009 - according to
preliminary figures - sales of EUR 14.7 million (-10% to the first
half of 2008).
Both periods still contain one-time effects. In the previous year,
within an initial order from a global partner, we registered orders
to the amount of EUR 1.6 million. In March 2009 we were able to sell
a product that does not belong anymore to the core business in the
amount of EUR 0.5 million. Without the consideration of these not
re-occurring revenues, the sales of the first half of 2009 decreased
slightly by 3%.
Within the cost reduction program, further measures were carried out
in the second quarter. These measures should show first effects on
the company's performance during the current financial year.
For the second half of 2009, aap expects a recovery of the demand and
along with the interest of global partner companies in aap's research
& development projects, improvements on the sales and revenue side.
The publication of the full aap Implantate AG six month report 2009
is scheduled for August 17, 2009.
aap is a medical technology company that develops, manufactures and
markets biomaterials and implants for trauma and orthopaedics. Its
product portfolio includes bone cements, bone graft substitutes,
antibiotic carriers, and implants for fracture healing and joint
replacement. In addition to its Berlin headquarters the company has
locations in Dieburg and Obernburg near Frankfurt am Main as well as
at Nijmegen in the Netherlands. aap Implantate AG has been listed in
the Prime Standard segment at the Frankfurt stock exchange since May
Please address any queries to:
aap Implantate AG, Nanette HÃ¼depohl, Head of Corporate
Communications, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; email@example.com
For further information about aap bio implants, visit
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660; ISIN:
DE0005066609; Index: CDAX, Prime All Share, TECH All Share;
Listed: Prime Standard in Frankfurter WertpapierbÃ¶rse, Freiverkehr in
Freiverkehr in BÃ¶rse DÃ¼sseldorf, Freiverkehr in Hanseatische
WertpapierbÃ¶rse zu Hamburg,
Freiverkehr in NiedersÃ¤chsische BÃ¶rse zu Hannover, Freiverkehr in
Bayerische BÃ¶rse MÃ¼nchen,
Freiverkehr in BÃ¶rse Stuttgart, Regulierter Markt in Frankfurter